Tiziana Life Sciences Share Discussion Threads

[abbynat] 06/7/2022 13:27

i read somewhere that the main man, has resigned. think its, the dr k , i can't remember his name!

[fandagle] 04/7/2022 11:36

Accustem shares diluted again! What a rip off

[one_frankel] 28/6/2022 11:06

Play the volatility as there's little value in holding for the longer-term yet!

...I'm not keen on Tlsa after past management endeavours but I still hold ACUT after the stock split and will continue to watch how it progresses in future!

...In terms of where I'm putting my money...Keeping a significant part of my powder dry currently but building relative positions with the intention of accumulating across a range of sectors predominantlyi in the US as its nigh impossible to time markets especially when that sc_um nation is involved but consider Energy Storage, Renewables, CyberSecurity amongst a host of others but who are sufficiently funded for their future aspirations...

Not too keen on BioPharma as its just too prolonged for any traction buddy!

[tricks08] 27/6/2022 23:38

I think you’re right on the sentiment Reb, it could take a while to return properly.
It still feels like any gains are just being sold into.
So where are you putting your money?
Any TLSA or ACUT?

[one_frankel] 27/6/2022 22:34

Absolutely wars have invariably been seen as a short-term catalyst for turning the cogs to to the economy when there's little else to sustain it but I think this anything but an abnormal market that has for far too long been continually pumped with the favorable fiscal policies of global governments and why we now see so many undercurrents brewing together simultaneously...

But I too believe the wider markets are pretty close to levelling out now but I think it will remain in consolidation phase until around the latter part of the year as bear markets take a little time for sentiment to return buddy.

[tricks08] 27/6/2022 22:08

Historically stock markets have always done well during wars.
Not the case this time…at the moment

[tricks08] 27/6/2022 22:01

That $57m raise was a smart piece of work by Gab. Expect another raise in Q4 or sooner even though there’s enough cash to go into next year. He won’t risk it.
Ultimately we all need the market to turn.
Or has it turned slightly already? Nasdaq biotech has been more buoyant in the last couple of weeks, can it be sustained?

[one_frankel] 27/6/2022 21:30

Well let's hope you're right Tricks because I haven't really been keeping tabs with ongoing developments at Tlsa but when there's been such a truly outstanding failure within the wider Bio sector and theres invariably a few more to follow shortly so becareful...

I also expect the market to start levelling around Sept onwards so start making that list as theres some real outstanding value starting to appear with growth especially in the US!

[fandagle] 27/6/2022 20:21

best 4 grand I ever lost this, opened my eyes to manipulation, thats when the fireside chats, dilutions, begging letters, sympathy requests and of course the Cayman Island accounts get topped up to keep the BOD's fine Cognac, jollies and dark beauties making count of monti cristo cigars on their thighs.......beware the wolf in the sheep clothing...

[stenick] 27/6/2022 14:20

hxxps://www.neurologylive.com/view/neurovoices-tanuja-chitnis-targeting-anti-cd3-biomarkers-progressive-multiple-sclerosis

[tricks08] 26/6/2022 18:04

Reb, the cash burn isn’t so great for TILS and there are no loans.
Cash runway takes them well into next year.
By then the market could very well look more rosy and there are some big inflection points before then anyway so it’s not time to press the panic button.

[one_frankel] 25/6/2022 19:31

Well if the unfortunate demise of 4D is anyway indicative to the sustainability of Tils, salvage what you can folks because I'm sure Tils will be heading for those similar troubled times in due course.

[jpuff] 16/6/2022 20:52

B.Riley Financial Thinks Tiziana Life Sciences' Stock is Going to RecoverSource: TipRanksB.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Tiziana Life Sciences (TLSA – Research Report) on June 13 and set a price target of $3.00. The company's shares closed last Thursday at $0.83, close to its 52-week low of $0.53. According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -32.2% and a 21.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Spectrum Pharmaceuticals. Currently, the analyst consensus on Tiziana Life Sciences is a Moderate Buy with an average price target of $4.00, representing a 406.3% upside.https://www.tipranks.com/news/blurbs/b-riley-financial-thinks-tiziana-life-sciences-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral

[jpuff] 11/6/2022 22:49

Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS PatientSource: GlobeNewswire Inc.Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug administration, today announces an interview with Chief Executive Officer and Chief Scientific Officer Kunwar Shailubhai, PhD and Proactive Investors discussing the positive clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program at the Brigham and Women's Hospital (BWH), Boston, MA.About Foralumab Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease. In a humanized mouse model (NOD/SCID IL2?c-/-), it was shown that while targeting the T-cell receptor, orally administered foralumab modulates immune responses of the T-cells and enhances regulatory T-cells (Tregs), thereby providing therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. Once a day treatment for 10 consecutive days with intranasal foralumab was not only well tolerated but it also produced strong clinical responses in COVID-19 patients. Based on these studies, the intranasal and oral administration of foralumab offers the potential to become a well-tolerated immunotherapy for autoimmune and inflammatory diseases by the induction of Tregs.About Tiziana Life SciencesTiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

[ic0gcds00] 11/6/2022 07:50

See latest rns

[ic0gcds00] 11/6/2022 07:50

No See latest rns

[one_frankel] 08/6/2022 15:36

Lean likes to be cryptic but if you figure it out, the key awaits to the road of riches FHasson!

[lean5gb] 08/6/2022 12:58

........ ... .. (chuckle)

[one_frankel] 03/6/2022 13:29

Ohh that old chestnut Puff!...Yes, patience, patience and some more everlasting patience!

[jpuff] 01/6/2022 20:59

It'll recover, patience needed

[one_frankel] 01/6/2022 17:17

The funny thing is that even my older and seemingly wiser uncle who was so believing of Tils potential has come to the dire conclusion that it is nothing more than a scam!

[jpuff] 01/6/2022 15:05

Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting

[jpuff] 31/5/2022 21:02

Added a few more

[michelle74] 30/5/2022 14:14

Yes big scam